Serum bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli

Gram-negative bacteria, especially Enterobacteriaceae, are the major cause both of community- and hospital-acquired urinary tract infections, which is worsened by the continuous emergence of antimicrobial resistance and a shortage of new antibiotics under development. The number of antimicrobial agents to treat infections caused by antimicrobial-resistant Enterobacteriaceae is limited, and the polymyxins such as colistin are considered the treatment of last resort [1].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research